Retension Pharmaceuticals, Inc.

Company Profile

Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The company was incorporated in 2023 and is headquartered in Falls Church, Virginia.

Founded

2023

Headquarters

MCLEAN, VA, United States

Website

www.retensionpharmaceuticals.com